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A bs tr ac t
Background
Used in combination with antiretroviral therapy, subcutaneous recombinant interleu-
kin-2 raises CD4+ cell counts more than does antiretroviral therapy alone. The clini-
cal implication of these increases is not known.
Methods
We conducted two trials: the Subcutaneous Recombinant, Human Interleukin-2 in 
HIV-Infected Patients with Low CD4+ Counts under Active Antiretroviral Therapy 
(SILCAAT) study and the Evaluation of Subcutaneous Proleukin in a Randomized Inter-
national Trial (ESPRIT). In each, patients infected with the human immunodeficien-
cy virus (HIV) who had CD4+ cell counts of either 50 to 299 per cubic millimeter 
(SILCAAT) or 300 or more per cubic millimeter (ESPRIT) were randomly assigned 
to receive interleukin-2 plus antiretroviral therapy or antiretroviral therapy alone. 
The interleukin-2 regimen consisted of cycles of 5 consecutive days each, adminis-
tered at 8-week intervals. The SILCAAT study involved six cycles and a dose of 4.5 
million IU of interleukin-2 twice daily; ESPRIT involved three cycles and a dose of 
7.5 million IU twice daily. Additional cycles were recommended to maintain the 
CD4+ cell count above predefined target levels. The primary end point of both stud-
ies was opportunistic disease or death from any cause.
Results
In the SILCAAT study, 1695 patients (849 receiving interleukin-2 plus antiretroviral 
therapy and 846 receiving antiretroviral therapy alone) who had a median CD4+ cell 
count of 202 cells per cubic millimeter were enrolled; in ESPRIT, 4111 patients (2071 
receiving interleukin-2 plus antiretroviral therapy and 2040 receiving antiretroviral 
therapy alone) who had a median CD4+ cell count of 457 cells per cubic millimeter 
were enrolled. Over a median follow-up period of 7 to 8 years, the CD4+ cell count was 
higher in the interleukin-2 group than in the group receiving antiretroviral therapy 
alone — by 53 and 159 cells per cubic millimeter, on average, in the SILCAAT study 
and ESPRIT, respectively. Hazard ratios for opportunistic disease or death from any 
cause with interleukin-2 plus antiretroviral therapy (vs. antiretroviral therapy alone) 
were 0.91 (95% confidence interval [CI], 0.70 to 1.18; P = 0.47) in the SILCAAT study 
and 0.94 (95% CI, 0.75 to 1.16; P = 0.55) in ESPRIT. The hazard ratios for death from 
any cause and for grade 4 clinical events were 1.06 (P = 0.73) and 1.10 (P = 0.35), 
respectively, in the SILCAAT study and 0.90 (P = 0.42) and 1.23 (P = 0.003), respec-
tively, in ESPRIT.
Conclusions
Despite a substantial and sustained increase in the CD4+ cell count, as compared 
with antiretroviral therapy alone, interleukin-2 plus antiretroviral therapy yielded no 
clinical benefit in either study. (ClinicalTrials.gov numbers, NCT00004978 [ESPRIT] 
and NCT00013611 [SILCAAT study].)
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The CD4+ cell count remains the best single indicator of immunodeficiency re-lated to infection with the human immuno-
deficiency virus (HIV) and is an important deter-
minant of clinical events defining the acquired 
immunodeficiency syndrome (AIDS) and other se-
rious diseases.1,2 Interleukin-2 is a cytokine secret-
ed by activated T cells that regulates the prolifera-
tion, differentiation, and survival of T cells. Early 
studies showed that Escherichia coli–expressed re-
combinant interleukin-2, given intravenously or 
subcutaneously in combination with antiretroviral 
therapy, increased the CD4+ cell count signifi-
cantly as compared with antiretroviral therapy 
alone.3-11 The cell expansions occur because of an 
increase in CD4+ T-cell survival (with half-lives that 
can exceed 3 years) and are characterized by an in-
crease in numbers of both naive and central mem-
ory cells.12-14 Absolute increases were greater in 
patients with higher baseline CD4+ cell counts. 
The level of HIV-associated immune activation, as 
reflected in T-cell turnover, was decreased in in-
terleukin-2 recipients.15
The clinical impact of CD4+ T-cell increases 
associated with the use of interleukin-2 is un-
known. Any possible beneficial effects from in-
terleukin-2 would need to be sufficiently large to 
mitigate the effect of its known toxicity. Since the 
net effects might differ between patients with 
higher CD4+ cell counts and those with lower 
counts, two trials were conducted involving pa-
tients receiving combination antiretroviral therapy.
Me thods
Study Design
The Subcutaneous Recombinant, Human Inter-
leukin-2 in HIV-Infected Patients with Low 
CD4+ Counts under Active Antiretroviral Therapy 
(SILCAAT) study and the Evaluation of Subcuta-
neous Proleukin in a Randomized International 
Trial (ESPRIT) were multicenter, international 
trials. The studies were open-label because the 
almost universal and typical side effects of inter-
leukin-2 made blinding impossible. Patients were 
randomly assigned, in equal numbers, to receive 
interleukin-2 plus antiretroviral therapy or anti-
retroviral therapy alone.
Recombinant interleukin-2 was administered 
subcutaneously in cycles. In the SILCAAT study, 
one cycle consisted of a dose of 4.5 million IU 
twice daily for 5 consecutive days. Six cycles of 
interleukin-2 were planned to be given, approxi-
mately 8 weeks apart, within the first 12 months 
of the study (the induction phase). The induction 
phase of ESPRIT consisted of three cycles of inter-
leukin-2 given at a dose of 7.5 million IU twice 
daily. After the induction phase, additional cycles 
of interleukin-2 therapy were recommended to 
maintain CD4+ cell counts above the predefined 
target levels. Guidelines for the management of 
interleukin-2 toxicity included reductions of the 
dose of interleukin-2 in decrements of 1.5 million 
or 3.0 million IU per dose. The minimum dose of 
interleukin-2 administered was 1.5 million IU 
twice daily. In the SILCAAT study, after the third 
cycle, the dose of interleukin-2 could be increased 
to 6.0 million or 7.5 million IU.
ESPRIT was funded and sponsored by the Na-
tional Institute of Allergy and Infectious Diseases 
(NIAID). The SILCAAT study was originally spon-
sored by Chiron. In February 2003, after complet-
ing enrollment, Chiron announced that it would 
no longer support the trial for business reasons 
owing to its inability to gain accelerated approval 
from the Food and Drug Administration on the 
basis of changes in CD4+ cell count. To complete 
the study, trial management was transferred to the 
SILCAAT Scientific Committee and the investiga-
tors conducting ESPRIT. NIAID provided regula-
tory sponsorship, and Chiron — and subsequent-
ly Novartis, after acquiring Chiron — provided 
funds for the SILCAAT study from February 2003 
forward. Chiron–Novartis provided the interleu-
kin-2 used in both trials.
The paper was written by a writing group rep-
resenting the leaders of each study. Neither Chi-
ron nor Novartis was involved in the data analysis 
or interpretation or in the preparation of the 
manuscript. Chiron and members of the SILCAAT 
Scientific Committee designed the SILCAAT study; 
members of the International Network for Strate-
gic Initiatives in Global HIV Trials (INSIGHT) 
Executive Committee designed ESPRIT. For the 
entire duration of ESPRIT and since 2003 for the 
SILCAAT study, oversight of data collection at 
clinical sites was performed by international co-
ordinating centers working with a central coor-
dinating center at the University of Minnesota, 
which managed and analyzed the data for both 
studies. The authors vouch for the accuracy and 
completeness of the data and analyses.
The ESPRIT design and methods have been 
reported previously.16 Additional information on 
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methods is given in the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org.
Study Populations
Both trials included adult patients with confirmed 
HIV-1 infection. Patients with a CD4+ cell count of 
50 to 299 per cubic millimeter (in the SILCAAT 
study) or 300 or more per cubic millimeter (in 
ESPRIT) were enrolled. Patients in the SILCAAT 
study were also required to have an HIV RNA level 
of less than 10,000 copies per milliliter. Protocols 
were approved by the institutional review board at 
each site. Written informed consent was obtained 
from all patients.
Assessments
Patients were seen every 4 months for a targeted 
history taking and clinical evaluation and mea-
surement of the CD4+ cell count and plasma HIV 
RNA level. Follow-up continued until a common 
closing date (November 15, 2008).
Definitions of End Points
The primary end point of each study was oppor-
tunistic disease or death from any cause. Second-
ary end points included death from any cause and 
grade 4 clinical events, defined as potentially life-
threatening events (excluding opportunistic dis-
eases) requiring medical intervention (see toxicity 
table at http://rcc.tech-res.com). Grade 4 events were 
reported irrespective of their perceived relation-
ship to the use of interleukin-2 or antiretroviral 
therapy and were coded according to the Medical 
Dictionary for Regulatory Activities (version 12.0).
Interim Monitoring of Safety and Efficacy
An independent data and safety monitoring board 
reviewed interim analyses from the SILCAAT study 
and ESPRIT. On November 27, 2007, at their final 
meeting, the board recommended that ESPRIT 
continue until its planned completion time (when 
320 primary events had occurred) and that the 
SILCAAT study continue until ESPRIT was closed.
Statistical Analysis
In both trials, the primary analysis was based 
on the intention-to-treat principle. Time-to-event 
methods were used to compare the groups receiv-
ing interleukin-2 plus combination antiretroviral 
therapy and combination antiretroviral therapy 
alone, with regard to major end points.17 Follow-up 
data were censored when patients were lost to fol-
low-up before or on November 15, 2008.
The hazard ratios for the comparisons of inter-
leukin-2 plus antiretroviral therapy and antiretro-
viral therapy alone were estimated from Cox mod-
els with a single indicator for treatment group. 
We tested the proportional-hazards assumption 
by including an interaction term between treat-
ment group and natural-log–transformed follow-
up time.
Data on the primary end point were summa-
rized for prespecified subgroups defined according 
to baseline characteristics. A total of 12 subgroup 
analyses were prespecified. The heterogeneity of 
hazard-ratio estimates between subgroups was as-
sessed by including an interaction term between 
treatment and subgroup in expanded Cox models. 
The results of subgroup analyses should be inter-
preted with caution; a significant interaction could 
be due to chance, because there was no adjustment 
made to the type 1 error for the number of sub-
groups examined.
Cox models were also used to obtain an esti-
mate of the association between the time-updated 
follow-up CD4+ cell count (the levels last measured 
before the event, hereafter called the latest levels) 
after log10 transformation and the primary end 
point among recipients of antiretroviral therapy 
alone. Estimates of parameters in Cox models and 
average differences in the CD4+ cell count be-
tween treatment groups during the follow-up pe-
riod were used to obtain predicted hazard ratios 
for comparison with observed hazard ratios.
Statistical analyses were performed using SAS 
software (version 9.1). P values are two-sided.
R esult s
Baseline Characteristics
A total of 1695 patients (849 receiving interleukin-2 
plus antiretroviral therapy and 846 receiving an-
tiretroviral therapy alone) in the SILCAAT study 
and 4111 patients (2071 receiving interleukin-2 plus 
antiretroviral therapy and 2040 receiving antiret-
roviral therapy alone) in ESPRIT were enrolled and 
had data included in the analysis (Table 1, and 
Fig. Ia and Ib in the Supplementary Appendix). 
The two treatment groups were well balanced with 
respect to baseline characteristics (Tables Ia and 
Ib in the Supplementary Appendix).
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Completeness of Follow-up
Approximately 5700 patient-years and 14,000 pa-
tient-years of follow-up were accrued in each group 
in the SILCAAT study and in ESPRIT, respectively. 
(The median duration of follow-up was 7.6 years 
for the SILCAAT study and 7.0 years for ESPRIT.) 
In the SILCAAT study, the status of the primary 
end point was unknown for 91 of the 849 patients 
(10.7%) receiving interleukin-2 and antiretroviral 
therapy and for 100 of the 846 patients (11.8%) 
receiving antiretroviral therapy alone. In ESPRIT, 
the status of the primary end point was unknown 
for 118 of the 2071 patients (5.7%) receiving in-
terleukin-2 and antiretroviral therapy and for 134 
of the 2040 patients (6.6%) receiving antiretrovi-
ral therapy alone.
Use of Interleukin-2
In the SILCAAT study, 72.3% of patients receiving 
interleukin-2 plus antiretroviral therapy completed 
six cycles of interleukin-2 therapy; 2.1% never re-
ceived interleukin-2. In ESPRIT, 83.4% of the pa-
tients receiving interleukin-2 plus antiretroviral 
therapy completed at least three cycles of interleu-
kin-2 therapy; 3.7% of patients never received in-
terleukin-2. The median number of cycles was 
7 (interquartile range, 5 to 9) in the SILCAAT study 
and 4 (interquartile range, 3 to 6) in ESPRIT.
CD4+ Cell Count
Median CD4+ cell counts are given in Figure 1. In 
the SILCAAT study, at 1 year, the median CD4+ cell 
count in the group receiving interleukin-2 plus an-
tiretroviral therapy had increased from the base-
line level by 131 per cubic millimeter (interquartile 
range, 52 to 215). For SILCAAT patients receiving 
antiretroviral therapy alone, the increase in the 
CD4+ cell count over the baseline value at 1 year 
was 32 per cubic millimeter (interquartile range, 
−11 to 78). The median difference in CD4+ cell 
count between the two SILCAAT groups declined 
from 99 per cubic millimeter at 1 year to 38 per 
cubic millimeter at 6 years. This decline paralleled 
the percentage of patients receiving interleukin-2 
during each year (97.8% in year 1 and 12.0% dur-
ing year 6). On average, over the follow-up period, 
the CD4+ cell count was higher with interleukin-2 
plus antiretroviral therapy than with antiretrovi-
ral therapy alone, by 53 per cubic millimeter (95% 
confidence interval [CI], 40 to 66).
In ESPRIT, the median CD4+ cell count was 
increased over the baseline value at 1 year, by 206 
cells per cubic millimeter (interquartile range, 55 
to 376) in the group receiving interleukin-2 plus 
antiretroviral therapy as compared with 21 cells 
per cubic millimeter (interquartile range, −64 to 
Table 1. Baseline Characteristics of Participants in SILCAAT and ESPRIT.*
Characteristic
SILCAAT Study 
(N = 1695)
ESPRIT 
(N = 4111)
Age (yr)
Median 40 40
Interquartile range 36–47 34–46
Female sex (%) 16.5 18.6
Race or ethnic group (%)†
Black  8.4  9.1
White 79.8 75.3
Other or unknown 11.8 15.5
CD4+ cell count (per mm3)
Median 202 457
Interquartile range 151–254 372–584
CD4+ cell-count nadir (per mm3)
Median 60 197
Interquartile range 26–107 91–306
HIV RNA ≤500 copies/ml (%) 81.4 79.7
AIDS event (%) 32.5 25.9
Body-mass index‡
Median 23.9 23.7
Interquartile range 21.8–26.1 21.9–25.9
Previous antiretroviral therapy (%)
PI 85.5 72.4
NNRTI 57.7 57.9
NRTI, PI, and NNRTI 44.3 38.5
Time since first prescribed antiretroviral 
drugs (yr)
Median 3.9 4.2
Interquartile range 1.8–7.2 2.2–6.4
Current antiretroviral regimen (%)
Includes PI 65.6 49.0
Includes NNRTI 45.8 46.3
Includes NRTI, PI, and NNRTI 13.9  7.9
* AIDS denotes the acquired immunodeficiency syndrome, HIV human immu-
nodeficiency virus, NNRTI nonnucleoside reverse-transcriptase inhibitor, 
NRTI nucleoside reverse-transcriptase inhibitor, and PI protease inhibitor.
† Race or ethnic group was self-reported.
‡ The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
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114) in the group receiving antiretroviral therapy 
alone. This difference between the two ESPRIT 
groups of 185 cells per cubic millimeter at 1 year 
declined to 113 cells per cubic millimeter at 
6 years. This decrease in the difference between 
the two groups paralleled the decline in receipt 
of interleukin-2 — from 96.2% of patients during 
the first year to 13.7% during the sixth year. On 
average, during the follow-up period, the CD4+ 
cell count was higher with interleukin-2 plus an-
tiretroviral therapy, by 159 per cubic millimeter 
(95% CI, 145 to 174), as compared with antiretro-
viral therapy alone.
Antiretroviral Therapy and HIV RNA Levels
During the follow-up period, the use of antiretro-
viral therapy and HIV RNA levels were similar for 
the groups receiving interleukin-2 plus antiretro-
viral therapy and the groups receiving antiretro-
viral therapy alone (Fig. IIa and IIb in the Supple-
mentary Appendix). More than 80% of patients 
had HIV RNA levels at or below 500 copies per 
milliliter at each visit.
Primary End Point and Other Major Clinical 
Outcomes
Opportunistic Disease or Death from Any Cause 
(Primary End Point)
In the SILCAAT study, 110 patients receiving inter-
leukin-2 plus antiretroviral therapy and 119 receiv-
ing antiretroviral therapy alone had an opportu-
nistic disease or died (Table 2 and Fig. 2A, and 
Tables IIa and IIIa in the Supplementary Appen-
dix) (hazard ratio for this primary end point with 
interleukin-2, 0.91; 95% CI, 0.70 to 1.18; P = 0.47). 
This hazard ratio did not vary significantly over 
the follow-up period (P = 0.34).
In ESPRIT, 159 patients receiving interleukin-2 
plus antiretroviral therapy and 165 receiving anti-
retroviral therapy alone had an opportunistic dis-
ease or died (Table 2, and Tables IIb and IIIb in the 
Supplementary Appendix). The hazard ratio for 
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Figure 1. Median CD4+ Cell Counts during the Study Period, According to Study and Treatment Group.
The median CD4+ cell counts are shown for the groups receiving interleukin-2 plus antiretroviral therapy (ARV) and 
the groups receiving ARV alone in the SILCAAT study and ESPRIT. The counts during the first 30 days after a cycle 
of interleukin-2 are not stable and therefore were excluded. Also shown are the percentages of patients assigned to 
receive interleukin-2 who were taking the drug during each year of the study.
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on July 5, 2017. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
Interleukin-2 for Patients with HIV Infection
n engl j med 361;16 nejm.org october 15, 2009 1553
this primary end point with interleukin-2 was 0.94 
(95% CI, 0.75 to 1.16; P = 0.55) (P = 0.40 for test of 
the proportional-hazards assumption).
We predicted the hazard ratios for the primary 
end point with interleukin-2 therapy on the basis 
of the overall differences in the CD4+ cell count 
between the two treatment groups in each study 
(on the log10 scale, 0.065 cells per cubic millime-
ter for the SILCAAT study and 0.099 cells per cubic 
millimeter for ESPRIT) and the relationship be-
tween the latest log10-transformed CD4+ cell count 
and the risk of opportunistic disease or death in 
the group receiving antiretroviral therapy alone in 
each study (Cox coefficient [±SE], −3.339±0.233 for 
the SILCAAT study and −3.049±0.187 for ESPRIT). 
The predicted hazard ratios for the SILCAAT study 
and ESPRIT were 0.80 (95% CI, 0.78 to 0.83) and 
0.74 (95% CI, 0.71 to 0.77, respectively). Each of the 
predicted hazard ratios is smaller than the corre-
sponding observed hazard ratio (which was 0.91 
for the SILCAAT study and 0.94 for ESPRIT).
Death from Any Cause
In the SILCAAT study, 81 patients receiving inter-
leukin-2 and antiretroviral therapy and 77 receiv-
ing antiretroviral therapy alone died (hazard 
ratio with interleukin-2, 1.06; 95% CI, 0.77 to 1.44; 
P = 0.73) (Table 2, Fig. 2B, and Table IIIa in the Sup-
plementary Appendix). The hazard ratio for deaths 
not attributable to opportunistic diseases (which 
occurred in 70 patients receiving interleukin-2 
plus antiretroviral therapy and 60 receiving anti-
retroviral therapy alone) was 1.17 with interleu-
kin-2 (95% CI, 0.83 to 1.66; P = 0.36).
In ESPRIT, 107 patients receiving interleukin-2 
and antiretroviral therapy and 116 receiving an-
tiretroviral therapy alone died (hazard ratio with 
interleukin-2, 0.90; 95% CI, 0.69 to 1.17; P = 0.42) 
(Table 2, and Table IIIb in the Supplementary Ap-
pendix). The hazard ratio for deaths not attribut-
able to opportunistic diseases (which occurred in 
97 patients receiving interleukin-2 and antiretro-
viral therapy and 106 receiving antiretroviral ther-
apy alone) was 0.89 (95% CI, 0.68 to 1.17; P = 0.41) 
with interleukin-2.
Opportunistic Diseases
In the SILCAAT study, an opportunistic disease de-
veloped in 49 patients receiving interleukin-2 and 
antiretroviral therapy and 66 receiving antiretro-
viral therapy alone (hazard ratio with interleukin-2, 
0.73; 95% CI, 0.51 to 1.06; P = 0.10). In ESPRIT, an 
opportunistic disease developed in 68 patients re-
ceiving interleukin-2 and antiretroviral therapy and 
63 receiving antiretroviral therapy alone (hazard ra-
tio with interleukin-2, 1.05; 95% CI, 0.75 to 1.48; 
P = 0.78) (Table 2, and Fig. III in the Supplemen-
tary Appendix).
Table 2. Hazard Ratios for the Primary End Point and Major Secondary End Points in SILCAAT and ESPRIT, According to 
Treatment Group.
End Point*
Interleukin-2 +  
Antiretroviral Therapy
Antiretroviral  
Therapy Alone
Hazard Ratio  
for Interleukin-2 
(95% CI) P Value
no. of patients (rate/100 person-yr)
SILCAAT
Primary end point: opportunistic 
disease or death from any cause
110 (1.94) 119 (2.13) 0.91 (0.70–1.18) 0.47
Death from any cause 81 (1.38) 77 (1.31) 1.06 (0.77–1.44) 0.73
Opportunistic disease 49 (0.86) 66 (1.18) 0.73 (0.51–1.06) 0.10
Grade 4 event 203 (3.93) 186 (3.58) 1.10 (0.90–1.34) 0.35
ESPRIT
Primary end point: opportunistic 
disease or death from any cause
159 (1.14) 165 (1.21) 0.94 (0.75–1.16) 0.55
Death from any cause 107 (0.75) 116 (0.83) 0.90 (0.69–1.17) 0.42
Opportunistic disease 68 (0.49) 63 (0.46) 1.05 (0.75–1.48) 0.78
Grade 4 event 466 (3.80) 383 (3.09) 1.23 (1.07–1.41) 0.003
* Grade 4 clinical events were defined as potentially life-threatening events (excluding opportunistic diseases) requiring 
medical intervention (see toxicity table at http://rcc.tech-res.com).
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Grade 4 Events
In the SILCAAT study, 203 patients receiving inter-
leukin-2 and antiretroviral therapy and 186 receiv-
ing antiretroviral therapy alone had a grade 4 event 
(hazard ratio with interleukin-2, 1.10; 95% CI, 0.90 
to 1.34; P = 0.35) (Table 2, and Fig. IV in the Sup-
plementary Appendix). In the interleukin-2 and 
antiretroviral therapy group, the 203 patients had 
a total of 342 grade 4 events, 78.4% of which oc-
curred more than 60 days after the last dose of 
interleukin-2 was administered. Gastrointestinal 
disorders and psychiatric disorders were more 
common in the interleukin-2 group (P = 0.02 and 
P = 0.03, respectively) (Table IVa in the Supplemen-
tary Appendix).
In ESPRIT, grade 4 adverse events occurred in 
466 patients receiving interleukin-2 and antiretro-
viral therapy and 383 receiving antiretroviral ther-
apy alone (hazard ratio with interleukin-2, 1.23; 
95% CI, 1.07 to 1.41; P = 0.003) (Table 2). In the 
interleukin-2 and antiretroviral therapy group, the 
466 patients had a total of 711 grade 4 events, 
82.4% of which occurred more than 60 days after 
the last dose of interleukin-2 was given. Differ-
ences between the two treatment groups were 
seen for the category of vascular disorders as 
well as the category of general disorders and 
administration site conditions (Table IVb in the 
Supplementary Appendix). Vascular events were 
seen in 40 patients receiving interleukin-2 and 
antiretroviral therapy and in 14 receiving anti-
retroviral therapy alone (hazard ratio with inter-
leukin-2, 2.80; 95% CI, 1.53 to 5.15; P<0.001). 
The most frequent type of vascular event was 
deep-vein thrombosis (affecting 10 patients re-
ceiving interleukin-2 and antiretroviral therapy 
and 2 receiving antiretroviral therapy alone).
Subgroup Findings
In both studies, hazard ratios for the primary end 
point with interleukin-2 were similar across de-
mographic subgroups (Fig. 3). In ESPRIT, among 
patients with a baseline CD4+ cell count below 450, 
the hazard ratio was 0.83 (95% CI, 0.62 to 1.12), 
whereas among those with counts of 450 or more, 
the hazard ratio was 1.09 (95% CI, 0.79 to 1.50) 
(P = 0.04 for the interaction between the CD4+ cell 
count and treatment group) (Fig. 3B). For these 
two baseline CD4+ cell-count subgroups in ESPRIT, 
the hazard ratios for death with interleukin-2 also 
differed significantly (P = 0.003): 0.68 (95% CI, 0.47 
to 0.98) for a count below 450 and 1.25 (95% CI, 
0.85 to 1.84) for a count of 450 or more.
Discussion
These studies confirm that intermittent use of in-
terleukin-2 is associated with substantial, sustained 
increases in CD4+ cell count. However, despite 
the increases in the CD4+ cell count, there was 
no clinical benefit, as measured by the reduction 
in the risk of opportunistic diseases or death, 
with interleukin-2 plus antiretroviral therapy as 
compared with antiretroviral therapy alone.
On the basis of the associations between the 
latest CD4+ cell count and the occurrence of op-
portunistic disease or death in the groups receiv-
ing antiretroviral therapy alone, the difference in 
the CD4+ cell count between the groups receiving 
interleukin-2 and antiretroviral therapy and those 
receiving antiretroviral therapy alone resulted in 
predicted hazard ratios for the primary end point 
with interleukin-2 of 0.80 for the SILCAAT study 
and 0.74 for ESPRIT. The predicted hazard ratios 
would be even smaller with adjustment for regres-
sion dilution bias resulting from variability in the 
measurement of the CD4+ cell count.18 It is un-
likely that treatment differences of these predict-
ed magnitudes were missed.
There are at least two hypotheses that could 
explain our results. The first and simplest is that 
the CD4+ T cells induced by interleukin-2 have no 
role in host defense. The second is that the cells 
are at least partially functional or that interleukin-2 
has some modest beneficial effect not mediated 
through CD4+ cells but negative effects of inter-
leukin-2 neutralize any improvements in host de-
fense conferred by the therapy.
The value of a given CD4+ T cell to its host is 
the net sum of the predetermined antigenic speci-
ficity of that cell and the effector functions it ex-
presses once activated by its antigen. T cells with 
receptors for irrelevant antigens or T cells that fail 
to exert protective effector functions on activa-
tion are of little value to the host. Interleukin-2 
is known to induce a polyclonal expansion of pre-
existing CD4+ T cells that have predominantly 
naive or central-memory phenotypes. Antiretro-
viral therapy leads to expansions of preexisting 
effector memory, central memory, and naive cells. 
In this regard, it is possible that, despite the ca-
pacity to respond in vitro to certain antigens and 
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Figure 3. Between-Group Differences in the CD4+ Cell Count and Hazard Ratios for Opportunistic Disease or Death from Any Cause  
(Primary End Point), According to Subgroup.
Panel A shows data for the SILCAAT study; and Panel B, for ESPRIT. The differences in the CD4+ cell count were calculated by subtract-
ing the count for the group receiving antiretroviral therapy (ARV) alone from the count for the group receiving interleukin-2 plus ARV 
and are expressed as means ±SE. Race or ethnic group was self-reported; the “other” category in Panel A consists of 1.2% Asians, 9.7% 
Hispanics, 0.8% other, and 0.1% unknown and in Panel B of 4.4% other and 0.3% unknown. The baseline CD4+ cell count is the approxi-
mate median value. In ESPRIT, one patient receiving ARV alone who had an event had missing data for baseline HIV RNA level.
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mitogens10 the antigenic specificities of cells ex-
panded with the use of interleukin-2 contribute 
little to the immediate needs of the host, where-
as cells expanded as a result of antiretroviral 
therapy include those of greatest current value — 
namely, those in the effector memory pool. In ad-
dition, the CD4+ cells expanded by means of in-
terleukin-2 express intermediate levels of CD25+, 
the alpha chain of the interleukin-2 receptor, as 
well as moderate levels of the transcriptional regu-
lator forkhead box P3 (FOXP3). In this regard, the 
CD4+ cells are similar, but not identical, to regu-
latory T cells — a subset of T cells associated with 
suppressor-cell activity. Thus, it is possible that 
even if correct antigenic specificities are present, 
effector functions exhibited by these cells could 
be different from those provided by CD4+ cells 
that are expanded in patients receiving antiretro-
viral therapy.
With regard to the second hypothesis, that ben-
efits of interleukin-2 are counteracted by negative 
effects of interleukin-2, in both the SILCAAT study 
and ESPRIT, patients who were receiving interleu-
kin-2 plus antiretroviral therapy had more grade 4 
events than those receiving antiretroviral therapy 
alone. Although many grade 4 events occurring in 
the interleukin-2 group occurred more than 60 
days after the completion of an interleukin-2 cy-
cle, they nonetheless appear to be related to receipt 
of interleukin-2. The association between occur-
rence of thromboembolic events and use of inter-
leukin-2 found in ESPRIT, coupled with the asso-
ciation between elevated d-dimer levels and death 
from any cause in patients with HIV infection19 
suggests a possible mechanism for a negative 
effect of interleukin-2 on clinical outcome. In 
ESPRIT, patients with higher baseline CD4+ cell 
counts had the greatest expansions of CD4+ T cells 
but also had a greater relative risk of having the 
primary end point or death from any cause. If this 
finding is not due to chance, it suggests that there 
may be clinically deleterious effects of interleukin-2 
that are more pronounced in patients with higher 
baseline CD4+ cell counts or greater increases in 
CD4+ T cells after the use of interleukin-2. The 
mechanisms behind these deleterious effects re-
main unclear but could be related to the effects of 
T regulatory cells, greater proinflammatory ef-
fects of interleukin-2 in patients with higher num-
bers of CD4+ cells, or both.
Earlier randomized trials of interleukin-2 were 
conducted in patients receiving mono- or dual-
nucleoside therapy, a different setting from that 
in the SILCAAT study and ESPRIT. In these ear-
lier studies, most patients had HIV RNA levels 
above 10,000 copies per milliliter, and the groups 
receiving antiretroviral therapy alone had de-
clining CD4+ cell counts.4,20,21 A pooled analy-
sis of the results from these earlier studies sug-
gested that patients treated with interleukin-2 
plus antiretroviral therapy, as compared with anti-
retroviral therapy alone, had higher CD4+ cell 
counts, lower viral loads, and a trend toward 
fewer opportunistic infections and death.22 A 
more recent study in patients with advanced HIV 
infection also showed a trend toward fewer AIDS-
defining illnesses with the use of interleukin-2.23 
One possible explanation for the differences be-
tween findings in the previous studies and our 
results is that interleukin-2 has some net benefi-
cial effect in a small subgroup of patients who 
have ongoing viral replication and a lower CD4+ 
cell count. A more likely explanation is that the 
treatment differences in the earlier studies were 
chance findings. This emphasizes the importance 
of conducting adequately powered, randomized 
trials to evaluate novel therapeutic strategies.
Surrogate markers often do not accurately pre-
dict the clinical effects of a treatment. The periph-
eral-blood total CD4+ cell count only partially 
explains the beneficial effects of antiretroviral 
therapy.24,25 These studies reaffirm that effects 
of a novel intervention that positively perturb lev-
els of prognostic markers need to be assessed and 
validated in trials with clinical end points before 
those markers can be deemed reliable surro-
gates regarding that intervention. This require-
ment is consistent with experiences in other dis-
eases.26
In summary, the results of the SILCAAT study 
and ESPRIT indicate that interleukin-2 offers no 
clinical benefit as compared with antiretroviral 
therapy alone. Whether these findings are relevant 
to other immunotherapies, such as interleukin-7,27 
is uncertain. The precise role of the immune sys-
tem in the pathogenesis of HIV infection may 
benefit from a reevaluation as a consequence of 
our results. Our data indicate that all CD4+ cells 
may not be equal with respect to host defense 
and that improvement in the prognostic or sur-
rogate value of CD4+ counts requires refinement 
in measurement.
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